Integrated Filing — IndAS



General information about company

Scrip Code 000000
NSE Symbol ZOTA
MSEI Symbol NOTLISTED
ISIN INE358U01012
Name of company ZOTA HEALTH CARE LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 22-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 15-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Manufacturing and marketing of pharmaceutical products
Start date and time of board meeting 22-05-2026   11:00:00
End date and time of board meeting 22-05-2026   18:15:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 22-05-2026
Indicate Company website link for updated RPT policy of the Company https://www.zotahealthcare.com/wp-content/uploads/2025/05/Related-Party-Transactions-Policy.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 4
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
During the quarter, the Company has not made any default on repayment of Loan. Further, the Company has not issued any Debt Securities till date.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 12,070.05 40,700.72
Other income 410.33 1,340.19
Total income 12,480.38 42,040.91
2 Expenses
(a) Cost of materials consumed 360.44 1,746.43
(b) Purchases of stock-in-trade 8,930.20 23,674.65
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (2,385.93) (2,550.99)
(d) Employee benefit expense 1,548.10 4,889.32
(e) Finance costs 8.34 25.26
(f) Depreciation, depletion and amortisation expense 125.32 395.45
(f) Other Expenses
1 Other Expenses 3,082.76 9,785.43
Total other expenses 3,082.76 9,785.43
Total expenses 11,669.23 37,965.55
3 Total profit before exceptional items and tax 811.15 4,075.36
4 Exceptional items (98.96) (98.96)
5 Total profit before tax 712.19 3,976.40
6 Tax expense
7 Current tax 264.00 1,084.41
8 Deferred tax (160.68) 101.33
9 Total tax expenses 103.32 1,185.74
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 608.87 2,790.66
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 608.87 2,790.66
17 Other comprehensive income net of taxes 23.22 38.02
18 Total Comprehensive Income for the period 632.09 2,828.68
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 3,463.26 3,463.26
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 85,356.94
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 1.77 8.48
Diluted earnings (loss) per share from continuing operations 1.77 8.48
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 1.77 8.48
Diluted earnings (loss) per share from continuing and discontinued operations 1.77 8.48
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) As per attachment



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 3,032.70
Capital work-in-progress 0.00
Investment property 0.00
Goodwill 0.00
Other intangible assets 409.24
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 54,787.97
Trade receivables, non-current 0.00
Loans, non-current 13,466.73
Other non-current financial assets
1 Other non-current financial assets 0.00
Total of other non-current financial assets 0.00
Total non-current financial assets 68,254.70
Deferred tax assets (net) (85.68)
Other non-current assets
1 Other non-current assets 0.00
Total of other non-current assets 0.00
Total non-current assets 71,610.96
2 Current assets
Inventories 8,317.67
Current financial asset
Current investments 0.00
Trade receivables, current 17,557.99
Cash and cash equivalents 0.70
Bank balance other than cash and cash equivalents 159.84
Loans, current 1,862.42
Other current financial assets
Total of other current financial assets 0.00
Total current financial assets 19,580.95
Current tax assets (net) 0.00
Other current assets
1 Other current assets 2,099.11
Total of other current assets 2,099.11
Total current assets 29,997.73
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 1,01,608.69
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 3,463.26
Other equity 85,356.94
Total equity attributable to owners of parent 88,820.20
Non controlling interest
Total equity 88,820.20
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Other non-current financial liabilities 0.00
Total of other non-current financial liabilities 0.00
Total non-current financial liabilities 0.00
Provisions, non-current 248.42
Deferred tax liabilities (net) 0.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Other non-current liabilities 0.00
Total of other non-current liabilities 0.00
Total non-current liabilities 248.42
Current liabilities
Current financial liabilities
Borrowings, current 2,189.64
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 2,146.29
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 5,498.32
Total Trade payable 7,644.61
Other current financial liabilities
1 Other current financial liabilities 0.00
Total of other current financial liabilities 0.00
Total current financial liabilities 9,834.25
Other current liabilities 978.88
1 Other current liabilities 978.88
Total of other current liabilities 978.88
Provisions, current 1,726.94
Current tax liabilities (Net) 0.00
Deferred government grants, Current 0.00
Total current liabilities 12,540.07
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 12,788.49
Total equity and liabilites 1,01,608.69
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block

Textual Information(1) As per attachment



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 DEFINED BENEFIT PLAN 31.03 50.81
Total Amount of items that will not be reclassified to profit and loss 31.03 50.81
2 Income tax relating to items that will not be reclassified to profit or loss 7.81 12.79
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 23.22 38.02



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 3,976.40
Adjustments for reconcile profit (loss)
Adjustments for finance costs 0.00
Adjustments for decrease (increase) in inventories (2,362.14)
Adjustments for decrease (increase) in trade receivables, current (7,254.10)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (1,659.40)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current (68.64)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 3,022.01
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 1,343.62
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 395.43
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 0.00
Adjustments for provisions, non-current 69.08
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 0.00
Adjustments for share-based payments 290.22
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (6,223.92)
Net cash flows from (used in) operations (2,247.52)
Dividends received 0.00
Interest paid (12.35)
Interest received (1,230.96)
Income taxes paid (refund) 1,097.19
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities (4,563.32)
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 2,054.56
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets (43,164.01)
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties (7,544.77)
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 1,230.96
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (51,532.38)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 58,574.72
Proceeds from issuing other equity instruments (4,303.85)
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 2,169.17
Repayments of borrowings 0.00
Payments of lease liabilities 0.00
Dividends paid 306.44
Interest paid 12.35
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 56,121.25
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 25.55
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 25.55
Cash and cash equivalents cash flow statement at beginning of period 134.98
Cash and cash equivalents cash flow statement at end of period 160.53





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Pradeep K Singhi & Associates Yes 31-03-2027


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 14-08-2024
Amount Raised 17,907.28
Report filed for Quarter ended 31-03-2026
Monitoring Agency Applicable
Monitoring Agency Name, if applicable CRISIL RATINGS LIMITED
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation
Comments of the Audit Committee after review The Committee has noted that there is no deviation/ variation and the issue have been fully utilized against the original objects till the quarter ended March 31, 2026.
Comments of the auditors, if any No comments
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Expansion of DAVAINDIA Project Not Applicable 14,325.83 0.00 14,325.83 0.00
2 Working capital requirement Not Applicable 2,686.09 0.00 2,686.09 0.00
3 General Corporate Purpose Not Applicable 895.36 0.00 895.36 0.00


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (2)

Amount in (Lakhs)

Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 20-02-2025
Amount Raised 12,341.00
Report filed for Quarter ended 31-03-2026
Monitoring Agency Applicable
Monitoring Agency Name, if applicable CRISIL RATINGS LIMITED
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation
Comments of the Audit Committee after review The Committee has noted that there is no deviation/ variation and the issue have been fully utilized against the original objects till the quarter ended March 31, 2026.
Comments of the auditors, if any No comments
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Expansion of DAVAINDIA Project FOFO Not Applicable 1,604.33 0.00 1,604.33 0.00
2 Expansion of DAVAINDIA Project COCO Not Applicable 7,651.42 0.00 7,651.42 0.00
3 Working capital requirement Not Applicable 1,234.10 0.00 1,234.10 0.00
4 General Corporate Purpose Not Applicable 1,851.15 0.00 1,851.15 0.00


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (3)

Amount in (Lakhs)

Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 17-04-2025
Amount Raised 7,155.00
Report filed for Quarter ended 31-03-2026
Monitoring Agency Not Applicable
Monitoring Agency Name, if applicable
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation
Comments of the Audit Committee after review The Committee has noted that there is no deviation/ variation and the issue have been fully utilized against the original objects till the quarter ended March 31, 2026.
Comments of the auditors, if any No comments
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Expansion of DAVAINDIA Project FOFO Not Applicable 930.15 0.00 930.15 0.00
2 Expansion of DAVAINDIA Project COCO Not Applicable 4,793.85 0.00 4,793.85 0.00
3 Working capital requirement Not Applicable 715.50 0.00 715.50 0.00
4 General Corporate Purpose Not Applicable 715.50 0.00 715.50 0.00


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (4)

Amount in (Lakhs)

Mode of Fund Raising QIP
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 17-12-2025
Amount Raised 34,999.99
Report filed for Quarter ended 31-03-2026
Monitoring Agency Applicable
Monitoring Agency Name, if applicable CRISIL RATINGS LIMITED
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation
Comments of the Audit Committee after review The Committee noted that during the quarter, no funds have been utilized against the stated objects.
Comments of the auditors, if any No comments
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Investment in DHML for setting-up of new COCO stores Not Applicable 12,962.50 0.00 0.00 0.00
2 Working Capital requirements Not Applicable 13,537.49 0.00 0.00 0.00
3 General Corporate Purpose Not Applicable 7,533.25 0.00 0.00 0.00


Signatory Details

Name of signatory Ashvin Variya
Designation of person Company Secretary and Compliance Officer
Place Surat
Date 22-05-2026




Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Zota Health Care Limited Himanshu Muktilal Zota Key Managerial Personnel Remuneration Salary of Rs. 3.5 lakh per month, Commission on sales 0.1% of annual turnover and sitting fees Rs. 5000 per meeting for attending meeting of the Board or Committees thereof 86.70 12.40 25.95
2 Zota Health Care Limited Kamlesh Rajnikant Zota Key Managerial Personnel Remuneration Salary of Rs. 3.5 lakh per month, Commission on sales 0.1% of annual turnover and sitting fees Rs. 5000 per meeting for attending meeting of the Board or Committees thereof 86.35 12.72 23.32
3 Zota Health Care Limited Moxesh Ketanbhai Zota Key Managerial Personnel Remuneration Salary of Rs. 3.5 lakh per month, Commission on sales 0.1% of annual turnover and sitting fees Rs. 5000 per meeting for attending meeting of the Board or Committees thereof 86.50 12.97 23.45
4 Zota Health Care Limited Viren Manukant Zota Key Managerial Personnel Remuneration Salary of Rs. 3.5 lakh per month, Commission on sales 0.1% of annual turnover and sitting fees Rs. 5000 per meeting for attending meeting of the Board or Committees thereof 86.45 12.93 23.32
5 Zota Health Care Limited Laxmi Kant Sharma Executive Director Remuneration Noted 5.77 1.34 1.07
6 Zota Health Care Limited Himanshu Muktilal Zota Key Managerial Personnel Dividend received Noted 31.36 0.00 0.00
7 Zota Health Care Limited Kamlesh Rajnikant Zota Key Managerial Personnel Dividend received Noted 19.91 0.00 0.00
8 Zota Health Care Limited Moxesh Ketanbhai Zota Key Managerial Personnel Dividend received Noted 4.94 0.00 0.00
9 Zota Health Care Limited Viren Manukant Zota Key Managerial Personnel Dividend received Noted 5.09 0.00 0.00
10 Zota Health Care Limited Ketan Chandulal Zota Non Executive Chairman Dividend received Noted 30.51 0.00 0.00
11 Zota Health Care Limited Varshabahen Gaurang Mehta Non Executive Independent Director Dividend received Noted 0.05 0.00 0.00
12 Zota Health Care Limited Vitrag Sureshkumar Modi Non Executive Independent Director Dividend received Noted 0.01 0.00 0.00
13 Zota Health Care Limited Bhumi Maulik Doshi Non Executive Independent Director Dividend received Noted 0.01 0.00 0.00
14 Zota Health Care Limited Jayshreeben Nileshkuamr Mehta Non Executive Independent Director Dividend received Noted 0.00 0.00 0.00
15 Zota Health Care Limited Ketan Chandulal Zota Non Executive Independent Director Remuneration Profit related commission of 0.30% on annual consolidated turnover and sitting fees Rs. 5000 per meeting for attending meeting of the Board or Committees thereof 83.20 0.27 75.97
16 Zota Health Care Limited Varshabahen Gaurang Mehta Non Executive Independent Director Any other transaction Sitting Fees Noted 1.05 0.41 0.68
17 Zota Health Care Limited Vitrag Sureshkumar Modi Non Executive Independent Director Any other transaction Sitting Fees Noted 1.05 0.27 0.77
18 Zota Health Care Limited Bhumi Maulik Doshi Non Executive Independent Director Any other transaction Sitting Fees Noted 0.90 0.27 0.63
19 Zota Health Care Limited Dhiren Prafulbhai Shah Non Executive Independent Director Any other transaction Sitting Fees Noted 0.90 0.23 0.63
20 Zota Health Care Limited Jayshreeben Nileshkuamr Mehta Non Executive Independent Director Any other transaction Sitting Fees Noted 1.00 0.23 0.72
21 Zota Health Care Limited Dhaval Chandubhai Patwa Non Executive Independent Director Any other transaction Sitting Fees Noted 0.75 0.24 0.59
22 Zota Health Care Limited Dr. Sujit Paul Key Managerial Personnel Any other transaction Salary & Commission Basic remuneration of Rs. 2.48 crore per annum, commission of 0.1% of annual consolidated turnover, International tour of which cost not exceeding Rs 36 lakhs per tour 160.16 39.12 72.32
23 Zota Health Care Limited Ashvin Variya Key Managerial Personnel Any other transaction Salary Salary upto Rs. 40 lakh per annum 37.94 3.11 3.15
24 Zota Health Care Limited Viral Mandviwala Key Managerial Personnel Any other transaction Salary Salary upto Rs. 16.50 lakh per annum 15.51 1.19 1.44
25 Zota Health Care Limited Niral M. Zota Promoter Group Any other transaction Salary & Commission Salary of Rs. 0.70 lakh per month and Commission on sales, 0.2% of annual turnover 15.20 6.09 11.48
26 Zota Health Care Limited Heli R. Shah Promoter Group Any other transaction Salary Salary of Rs. 0.15 per month 0.66 0.11 0.11
27 Zota Health Care Limited Ashvin Variya Key Managerial Personnel Loan 30.00 Approved 0.00 32.00 33.12 Textual Information(1)
28 Zota Health Care Limited Stuti Moxesh Zota Director's immediate relative Any other transaction Salary Salary upto Rs. 1 lakh per month 0.42 0.36 0.00
29 Zota Health Care Limited Davaindia Health Mart Limited Subsidiaries Sale of goods or services 30,000.00 Approved 12,922.25 (7,463.67) 11,515.38
30 Zota Health Care Limited Everyday Herbal Beauty Care Limited Subsidiaries Purchase of goods or services 2,500.00 Approved 1,323.08 147.93 (79.59)
31 Zota Health Care Limited Davaindia Health Mart Limited Subsidiaries Loan Noted 6,325.14 9,558.79 13,455.71 Loan 7.300 10 years Unsecured For working capital requirements Textual Information(2)
32 Zota Health Care Limited Everyday Herbal Beauty Care Limited Subsidiaries Loan 4,000.00 Approved 319.28 816.06 0.00 Loan 7.300 10 years Unsecured For working capital requirements Textual Information(3)
33 Zota Health Care Limited Curexis Ventures Private Limited Subsidiaries Loan Noted 151.05 0.00 151.05 Loan 7.300 5 years Unsecured For working capital requirements Textual Information(4)
34 Zota Health Care Limited Davaindia Health Mart Limited Subsidiaries Investment Noted 19,529.53 0.00 0.00
35 Zota Health Care Limited Everyday Herbal Beauty Care Limited Subsidiaries Investment Noted 1,947.00 0.00 0.00
36 Zota Health Care Limited Curexis Ventures Private Limited Subsidiaries Investment Noted 1.00 0.00 0.00
37 Zota Health Care Limited KMHP Ventures Limited Subsidiaries Investment Noted 10.00 0.00 0.00
38 Zota Health Care Limited Sushant Bhattacharya Senior Managerial Personnel Any other transaction Purchase of shares 0.50 Approved 0.50 0.00 0.00
39 Davaindia Health Mart Limited Hakishan Ambaram Jani Director of Wholly Owned Subsidiay Remuneration Noted 7.28 1.02 1.04
40 Davaindia Health Mart Limited Vitrag Sureshkumar Modi Independent Director of Wholly Owned Subsidiary Any other transaction Sitting Fees Noted 0.55 0.67 1.13
41 Davaindia Health Mart Limited Dhaval Chandubhai Patwa Independent Director of Wholly Owned Subsidiary Any other transaction Sitting Fees Noted 0.45 0.20 0.59
42 Everyday Herbal Beauty Care Limited Rajesh Vanechand Kubadiya Director of Subsidiary Remuneration Noted 7.50 1.25 1.25
43 Everyday Herbal Beauty Care Limited Arvind Vanechand Kubadiya Director of Subsidiary Remuneration Noted 7.50 7.25 1.25
44 Everyday Herbal Beauty Care Limited Rajesh Vanechand Kubadiya Director of Subsidiary Loan Noted 0.00 27.28 27.94 Textual Information(5)
Total value of transaction during the reporting period 43,314.50



Text Block

Textual Information(1) The loan amount includes principle outstanding and interest
Textual Information(2) The loan amount includes principle outstanding and interest
Textual Information(3) The loan amount includes principle outstanding and interest
Textual Information(4) The loan amount includes principle outstanding and interest
Textual Information(5) The loan amount includes principle outstanding and interest